Risteys · L12

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — L59.0 Cause of death: ICD-10 — L59.0 2 out of 7 registries used, show all original rules.	25
4. Check minimum number of events None	25
5. Include endpoints None	25
6. Filter based on genotype QC (FinnGen only)	25

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	182	103	76
Only index persons	161	98	63
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	46.31	50.89	40.11
Only index persons	45.56	49.33	39.70

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	25	19	6
Unadjusted period prevalence (%)	0.01	0.01	0.00
Median age at first event (years)	47.47	49.59	40.75

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

7.16

3.80

5.8

4.2

197.3

219.4

u/l

—

(3009508) Creatinine [Moles/volume] in Urine

4.03

2.87

3.9

1.9

7.6

8.3

mmol/l

—

(3037522) Nuclear Ab [Titer] in Serum

4.09

2.46

1.6

1.4

—

693.3

—

(3020630) Protein [Mass/volume] in Serum or Plasma

4.91

1.92

1.0

1.2

68.3

66.8

g/l

—

(42870588) Differential panel, method unspecified - Blood

3.03

1.87

10.7

5.0

—

(3026493) Urate [Moles/volume] in Serum or Plasma

3.07

1.83

3.9

2.0

356.8

321.4

umol/l

0.33

(3012516) Albumin [Mass/volume] in Urine

2.99

1.76

3.9

2.1

167.1

28.5

mg/l

—

(3000991) Gas panel - Venous blood

3.40

1.43

1.4

9.9

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

2.78

1.40

5.3

3.3

—

(3022145) Colonoscopy Study observation

3.20

1.35

1.0

1.4

—

(3037467) Urinalysis macro (dipstick) panel - Urine

147

2.79

1.29

3.7

3.9

—

(3012544) pH of Venous blood

3.02

1.28

1.6

2.7

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

1.05

0.0

1.6

—

(40768797) Stomach Pathology biopsy report

2.49

0.99

1.0

1.3

—

(40768804) Tissue Pathology biopsy report

1.97

0.81

2.8

1.9

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.98

0.78

1.4

1.8

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

2.24

0.77

2.0

1.6

—

(3024561) Albumin [Mass/volume] in Serum or Plasma

1.89

0.73

5.4

3.7

35.0

34.7

g/l

0.04

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.88

0.71

1.9

2.0

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

1.86

0.69

2.4

2.5

66.3

86.5

ug/l

0.53

(3031040) Bacteria [#/volume] in Urine by Automated count

144

1.89

0.69

4.7

4.1

—

137.8

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

132

1.90

0.69

3.6

4.7

7.8

6.4

mmol/l

0.72

117

(3015736) pH of Urine

1.87

0.68

3.8

3.4

—

(3000494) Fungus identified in Specimen by Culture

1.90

0.67

2.0

1.3

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.61

0.0

1.3

—

(3026008) Bacteria identified in Urine by Culture

1.78

0.58

3.6

2.9

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.75

0.55

3.6

2.7

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

1.72

0.54

1.1

1.2

—

18.9

—

(40760892) CBC W Ordered Manual Differential panel - Blood

1.59

0.51

1.9

4.8

—

(1002224) Polysomnography panel

0.00

0.42

0.0

1.2

—

(3044889) 12 lead EKG panel

146

1.51

0.40

3.5

3.3

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

1.56

0.39

2.0

1.7

392.0

481.3

pmol/l

—

(3023368) Bacteria identified in Blood by Culture

1.52

0.39

4.2

2.9

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

1.55

0.36

2.1

—

(3033658) Prothrombin time (PT) actual/Normal

1.48

0.35

9.7

3.3

95.0

88.8

—

(3044640) Blood type and Crossmatch panel - Blood

1.34

0.30

2.8

2.1

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.27

0.23

1.6

1.5

—

(40758310) Human epididymis protein 4 [Moles/volume] in Serum or Plasma

0.00

0.22

0.0

1.4

—

70.6

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.22

0.0

2.6

—

(46236952) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)

0.00

0.22

0.0

4.2

—

53.6

—

(40768793) Breast Pathology biopsy report

0.00

0.22

0.0

1.5

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.21

0.0

1.4

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.21

0.0

1.4

—

(36304419) Bacteria [Presence] in Urine

1.35

0.21

2.9

2.4

—

(3041096) Erythrocytes [Presence] in Urine by Automated

1.26

0.20

1.6

3.4

—

(3013512) EKG study

1.23

0.20

3.3

3.2

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

1.29

0.19

4.9

3.8

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.24

0.11

1.4

1.7

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

104

1.10

0.01

3.3

4.4

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

142

0.97

0.00

3.1

4.2

—

(1761868) Lipid panel - Serum or Plasma

0.91

0.00

2.3

2.5

—

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

1.00

0.00

1.7

2.4

47.0

60.2

u/l

—

(4268621)

0.00

0.0

2.0

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

0.0

1.5

—

(3023410) Appearance of Cerebral spinal fluid

0.00

0.0

1.2

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

0.00

0.0

1.9

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

4.8

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.0

4.4

—

22.0

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

0.00

0.0

1.0

—

(3026725) Estradiol (E2) [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

1.0

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.00

0.0

1.0

—

(3012413) Glucose [Moles/volume] in Serum or Plasma --2 hours post meal

0.00

0.0

1.4

—

(3044290) Cell count panel - Cerebral spinal fluid

0.00

0.0

1.4

—

(3008898) HLA-B27 [Presence]

0.00

0.0

1.1

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.0

1.2

—

(3003694) ABO and Rh group [Type] in Blood

1.04

0.00

1.4

1.5

—

(3021901) Oxygen saturation in Capillary blood

0.00

0.0

1.4

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.0

—

(4034850)

0.00

0.0

7.3

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

0.00

0.0

1.8

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

4.6

—

45.7

—

(3028626) Oxygen [Partial pressure] in Capillary blood

0.00

0.0

1.4

—

8.3

—

(3007930) Methemoglobin/Hemoglobin.total in Blood

0.00

0.0

3.6

—

0.8

—

(3045414) Leukocytes [Presence] in Urine

0.00

0.0

2.0

—

(40758558) Short blood count panel - Blood

1.05

0.00

18.0

7.1

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.0

1.4

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.0

1.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint L12_ABIGNE and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_ABIGNE.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: L12_ABIGNE – Erythema ab igne [dermatitis ab igne]

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

NAME	L12_ABIGNE
CONTROL_EXCLUDE	L12_RADIATIONRELATEDSKIN
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	L590
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	L590
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Erythema ab igne [dermatitis ab igne]

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints